Type of MRI contrast, Tissue gadolinium, And fibrosis

American Journal of Physiology - Renal Physiology

Volumn 307, Issue 7, 2014, Pages F844-F855

  Do, Catherine ^a   Barnes, Jeffrey L ^a,b   Tan, Chunyan ^a   Wagner, Brent ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Animals; Fibrosis; Gadolinium adverse effects; Magnetic resonance imaging adverse effects; Nephrogenic fibrosing dermopathy; Skin diseases

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CELL PROTEIN; CONTRAST MEDIUM; FIBRONECTIN; GADODIAMIDE; GADOLINIUM; GADOTERIDOL; MYOFIBROBLAST STRESS FIBER PROTEIN; PARAFFIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; GADOLINIUM PENTETATE; HETEROCYCLIC COMPOUND; ORGANOMETALLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; ENERGY DISPERSIVE X RAY SPECTROSCOPY; FEMALE; FIBROBLAST; FIBROSIS; IN VITRO STUDY; KIDNEY PROXIMAL TUBULE; LIVER; MUSCLE; MYOFIBROBLAST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RAT; ROENTGEN SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; SKIN; SPLEEN; STRESS FIBER; UNINEPHRECTOMY; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; CHEMISTRY; COMPLICATION; FISCHER 344 RAT; HUMAN; KIDNEY FAILURE; METABOLISM; NEPHROGENIC SYSTEMIC FIBROSIS; THERMODYNAMICS;

ANIMALS; CELLS, CULTURED; CONTRAST MEDIA; FEMALE; FIBROBLASTS; FIBRONECTINS; GADOLINIUM; GADOLINIUM DTPA; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; RATS, INBRED F344; RENAL INSUFFICIENCY; THERMODYNAMICS;

EID: 84907546489     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00379.2014     Document Type: Article

References (40)

1. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 166: 7556–7562, 2001.
2. Agarwal R, Brunelli SM, Williams K, Mitchell MD, Feldman HI, Umscheid CA. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 24: 856-863, 2009.
3. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 30: 1259-1267, 2009.
4. American College of Radiology. ACR Manual on Contrast Media (online). http://www.acr.org/∼/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2013_Contrast_Media.pdf [18 August 2014].
5. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest 87: 858-870, 2007.
6. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56: 27-30, 2007.
7. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 25: 358, 2003.
8. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23: 383-393, 2001.
9. Edward M, Quinn JA, Mukherjee S, Jensen MB, Jardine AG, Mark PB, Burden AD. Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 214: 584-593, 2008.
10. European Medicines Agency. Questions and answers on the review of gadolinium-containing contrast agents (online). http://www.ema.euro_pa.eu/docs/en_GB/document_library/Referrals_document/gadolinium_31/WC500015635.pdf; 18 August 2014.
11. Faulkner JL, Szcykalski LM, Springer F, Barnes JL. Origin of interstitial fibroblasts in an accelerated model of angiotensin II-induced renal fibrosis. Am J Pathol 167: 1193-1205, 2005.
12. Gorin Y, Kim NH, Feliers D, Bhandari B, Choudhury GG, Abboud HE. Angiotensin II activates Akt/protein kinase B by an arachidonic acid/redox-dependent pathway and independent of phosphoinositide 3-ki-nase. FASEB J 15: 1909-1920, 2001.
13. Haylor J, Dencausse A, Vickers M, Nutter F, Jestin G, Slater D, Idee JM, Morcos S. Nephrogenic gadolinium biodistribution and skin cellu-larity following a single injection of Omniscan in the rat. Invest Radiol 45: 507-512, 2010.
14. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 21-26, 2007.
15. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20: 563-576, 2006.
16. Jimenez SA, Artlett CM, Sandorfi N, Derk C, Latinis K, Sawaya H, Haddad R, Shanahan JC. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50: 2660-2666, 2004.
17. Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 51: 966-975, 2008.
18. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 233: 109-122, 2008.
19. Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 21: 123-128, 2008.
20. Lee CU, Wood CM, Hesley GK, Leung N, Bridges MD, Lund JT, Lee PU, Pittelkow MR. Large sample of nephrogenic systemic fibrosis cases from a single institution. Arch Dermatol 145: 1095-1102, 2009.
21. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35: 238-249, 2006.
22. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 21: 129-134, 2008.
23. Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens 18: 519-525, 2009.
24. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 4: 461–469, 2009.
25. Pietsch H, Raschke M, Ellinger-Ziegelbauer H, Jost G, Walter J, Frenzel T, Lenhard D, Hutter J, Sieber MA. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol 46: 48–56, 2011.
26. Port M, Idee JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 21: 469–490, 2008.
27. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (Pro-Hance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 3: 747–751, 2008.
28. Runge VM. Safety of magnetic resonance contrast agents. In: Magnetic Resonance Procedures: Health Effects and Safety, edited by Shellock FG. Boca Raton, FL: CRC, 2001, p. 241–259.
29. Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, Seybold V, Vogt T, Banas B, Hofstaedter F, Kramer BK. Ultrastruc-tural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 3: 968–975, 2008.
30. Sherry AD, Caravan P, Lenkinski RE. Primer on gadolinium chemistry. J Magn Reson Imaging 30: 1240–1248, 2009.
31. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 43: 65–75, 2008.
32. Singh M, Davenport A, Clatworthy I, Lewin J, Deroide F, Hubbard V, Rustin MH. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger? Br J Dermatol 158: 1358–1362, 2008.
33. Spencer AJ, Wilson SA, Batchelor J, Reid A, Rees J, Harpur E. Gadolinium chloride toxicity in the rat. Toxicol Pathol 25: 245-255, 1997.
34. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3: 349-363, 2002.
35. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 30: 372-380, 1995.
36. van der Molen AJ. Nephrogenic systemic fibrosis and the role of gadolinium contrast media. J Med Imaging Radiat Oncol 52: 339-350, 2008.
37. 153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. Magn Reson Med 64: 1274-1280, 2010.
38. Wagner B, Ricono JM, Gorin Y, Block K, Arar M, Riley D, Choud-hury GG, Abboud HE. Mitogenic signaling via platelet-derived growth factor (3 in metanephric mesenchymal cells). J Am Soc Nephrol 18: 2903-2911, 2007.
39. Wagner B, Tan C, Barnes JL, Ahuja SS, Davis TL, Gorin Y, Jimenez F. Nephrogenic systemic fibrosis: evidence for bone marrow-derived fibrocytes in skin, liver, and heart lesions using a 5/6 nephrectomy rodent model. Am J Pathol 181: 1941-1952, 2012.
40. Wermuth PJ, Jimenez SA. Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Clin Exp Immunol 175: 113-125, 2014.